Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of Buy by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price […]

Related Keywords

Canada ,United States ,Wildon Farwell ,Stifel Nicolaus ,Piper Sandler ,Raymond James ,Zurcher Kantonalbank Zurich Cantonalbank ,Allspring Global Investments Holdings ,Ameritas Investment Partners Inc ,Nasdaq ,Sphera Funds Management ,Dyne Therapeutics Company Profile ,Royal Bank ,Securities Exchange Commission ,Dyne Therapeutics Inc ,Dyne Therapeutics ,Get Free Report ,Marketbeat Ratings ,Exchange Commission ,Gatti High ,Investment Partners ,Kantonalbank Zurich Cantonalbank ,Global Investments Holdings ,Get Free ,Dyne Therapeutics Daily ,Nasdaq Dyn ,Ladyn ,Medical ,Ratings ,Consensus ,